0% found this document useful (0 votes)
542 views1 page

Algoritma Statin

The document provides major recommendations for statin therapy for atherosclerotic cardiovascular disease prevention from the 2013 ACC/AHA guidelines. It recommends high or moderate intensity statins depending on factors like age and disease risk. It also provides dosing guidance for high and moderate intensity statins.
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
542 views1 page

Algoritma Statin

The document provides major recommendations for statin therapy for atherosclerotic cardiovascular disease prevention from the 2013 ACC/AHA guidelines. It recommends high or moderate intensity statins depending on factors like age and disease risk. It also provides dosing guidance for high and moderate intensity statins.
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd

Major Recommendations for Statin Therapy for

Guidance for High-Intensity and


Atherosclerotic Cardiovascular Disease Prevention Moderate Intensity Statin Dosing
2013 ACC/AHA Blood Cholesterol Guideline
Patients over 21 years old and High-Intensity Statins
candidate for statin therapy • Atorvastatin 40-80 mg
• Rosuvastatin 20-40 mg

Moderate-Intensity Statins
Clinical
Yes Age ≤ 75 and Yes High-Intensity Statin • Atorvastatin 10–20 mg
atherosclerotic
candidate for high- Daily dose lowers LDL-C • Rosuvastatin 5–10 mg
cardiovascular
intensity statin by approx ≥ 50%
disease • Simvastatin 20–40 mg
• Pravastatin 40–80 mg
No Moderate-Intensity Statin
No Daily dose lowers LDL-C • Lovastatin 40 mg
by approx 30-50% • Fluvastatin XL 80 mg
• Fluvastatin 40 mg bid
Yes • Pitivastatin 2–4 mg
LDL-C ≥ 190 mg/dl High-Intensity Statin

Yes Patients over age 75


High-Intensity Statin
No For patients with clinical CVD, moderate-to-high
intensity statins if tolerated.
For all other indications, consider comorbidities,
Type 1 or 2 Yes Estimated 10 yr No safety, and priorities of care before initiating or
Diabetes atherosclerotic CVD Moderate-Intensity Statin
age 40-75 risk ≥ 7.5% continuing statin therapy.
Calcium Scoring Considerations
For individuals at intermediate risk (5%-7.5%) or
No
those who are unsure about their risk, consider
calcium scoring.
Age 40-75 A CAC score of zero is associated with a very low
Estimated 10 yr Yes Moderate-to-High- CVD event rate and those individuals are unlikely to
atherosclerotic CVD Intensity Statin benefit from statin therapy.*
risk > 7.5%
A CAC score ≥100 is associated with an elevated
risk of a CVD event (> 20%) regardless of traditional
No Algorithm adapted from Stone NJ, et. al. 2013 ACC/AHA guideline
risk factors.*
on the treatment of blood cholesterol to reduce atherosclerotic
If risk is 5-7.5%, consider moderate
cardiovascular risk in adults: a report of the American College of Online CVD Risk Calculator
Cardiology/American Heart Association Task Force on Practice
intensity statin if: LDL > 160 mg/dl, Guidelines. Circulation 2013; 0000437738.63853.7a
Go to www.heart.org and search “cv risk calculator”
family history, hs CRP > 2, CAC>300 for online web application.
*Calcium scoring considerations are provided by Minneapolis Heart
or 75%, ABI < .9, or high lifetime risk. Institute® and are not part of the official ACC/AHA Guidelines.

Minneapolis Heart Institute®


mplsheart.com Center for Preventive Cardiology
S413160 20871 0714 ©2014 ALLINA HEALTH SYSTEM. TM A TRADEMARK
OF ALLINA HEALTH SYSTEM. MINNEAPOLIS HEART INSTITUTE® AND
612-863-3900
MHI® ARE TRADEMARKS OF MINNEAPOLIS HEART INSTITUTE®, INC.

You might also like